Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus platinum-gemcitabine versus placebo plus platinum-gemcitabine as first-line treatment for PD-L1-positive advanced or metastatic urothelial carcinoma
CTR20201856Phase 3Active
- Sponsor
- Suzhou Union Biopharm
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, sponsored by Suzhou Union Biopharm. Started Sep 2020; status: active.
02
Drugs
toripalimab
Beyond the preview
Go deeper on CTR20201856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201856.